Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

Aditi Singh; Arthi Sridhar; Aastha Poddar; Anastasios Dimou; Kaushal Parikh; Mohamed Shanshal; Anna Schwecke; Nicole Moffett; Manish R Patel; Aaron S Mansfield; Konstantinos Leventakos

doi:10.1016/j.jtocrr.2025.100807

Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report

JTO Clin Res Rep. 2025 Feb 13;6(6):100807. doi: 10.1016/j.jtocrr.2025.100807. eCollection 2025 Jun.

Affiliations

¹ Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
² Department of Health Sciences Research, Mayo Clinic, College of Medicine, Rochester, Minnesota.
³ Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota.

Abstract

Third-generation tyrosine kinase inhibitors are effective treatment of EGFR-mutated NSCLC. After an initial response, patients on this therapy ultimately develop resistance leading to disease progression. One of the resistance mechanisms is histological transformation to SCLC. There is no standard of care for the management of transformed SCLC. Given the rarity of transformed SCLC, it is important to study treatment options that are safe and effective for this disease. In this case series, three patients received treatment with lurbinectedin plus osimertinib after transformation to SCLC. In our limited experience, the combination was found to be safe.

Keywords: Drug resistance; EGFR; Lurbinectedin; NSCLC; Osimertinib; SCLC; Tranformed SCLC.